

COG PROTOCOL ACNS0126

A PHASE II STUDY OF TEMOZOLOMIDE IN THE TREATMENT OF CHILDREN WITH HIGH GRADE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMAS

- Instructions and data required for the submission of digital treatment planning information on this protocol are provided below. Institutions submitting digital treatment planning data must also submit hardcopy of isodose distributions in three orthogonal planes, showing target volumes as well. Institutions must notify QARC by email at ATCDICOMRT@QARC.org that data have been submitted. The email message should state your institution and include the protocol, the patient's case number, initials, and a list of the data that have been submitted.
- Digital Data to be submitted
 - Volumetric planning CT
 - Structure contours delineating target volumes and critical structures
 - Plans and 3-D Dose distributions for the individual fraction groups and for the total dose plan in absolute dose
 - Dose-volume histograms for the total dose plan in absolute dose for PTV1 and PTV2, if treated, and for the following organs at risk (see protocol Sections 10.5 and 11.5):
 - Globes and lenses of the eyes
 - Optic nerves and chiasm
 - Spinal cord
 - Cochlea
 - Pituitary gland
 - Brainstem
- How to Submit Digital Data

This method of submission has been developed with the Advanced Technology Consortium (NIH grant CA81647) using the software and methodology developed by the ITC (Image-guided Therapy Center).

Details for the submission of digital data are at [QARC_digital_data_submission](#)

Please see protocol Sections 10.7 and 11.6 for the complete list of QA materials to be submitted and the required timelines.

Questions should be addressed to ATCDICOMRT@QARC.org or please call 401-454-4301.